PATH EX, Inc. Announces Successful $5 Million Financing Round to Advance CycloPE(R), a Breakthrough Treatment for Sepsis
HOUSTON, TEXAS / ACCESS Newswire / May 8, 2025 / PATH EX, Inc., a medical device company located in the Texas Medical Center Innovation Factory, is excited to announce the successful completion of a $5 million financing round. This investment was led by IAG Capital Partners and supported by the TMC Venture Fund and Fitz Gate Ventures. The capital raised will accelerate the development and future commercialization of CycloPE®, a medical device designed to rapidly eradicate bacteria from the bloodstream in patients suffering from sepsis.
Sepsis is a life-threatening condition caused by the body’s response to infection and affects millions of people worldwide each year. The CycloPE® device would represent a significant advancement in sepsis treatment, offering a potentially lifesaving intervention for patients with limited treatment options.
